Company Performance Metrics
- Christina T. Purdue: Executive Vice President, Legal General Counsel and chief human resources officer
- Bernald B. Washington: Executive vice president, Genventis Manufacturing Division
Genventis is an early-stage biopharmaceutical company developing high-precision cell therapies for the treatment of cancer, immune and neurological conditions, autoimmune disorders, and rare diseases. Its investigational pipeline is focused on replacing a patient’s diseased blood and immune system with a healthy one, with the goal of delivering
transformative, potentially curative therapies.
The company’s proprietary manufacturing platform leverages single-cell precision to create uniquely defined products, advancing the potential of scalable, next-generation allogeneic cell therapies. Guided by scientific rigor and innovation, this approach is designed to enable consistent, high-quality cellular medicines.
Genventis brings together a team of leading scientists, engineers, and clinicians united by a shared mission—to transform the lives of patients. Together, they are working to deliver the promise of a cure without compromise.
Please note: Official communications from Genventis are conducted exclusively through @genventis.com email addresses.
